In Situ PEG Modification of CAR-T Cells Can Alleviate Cytokine Release Syndrome and Neurotoxicity

In recent years, cancer researchers have cheered the arrival of chimeric antigen receptor (CAR) T-cell therapy, which has achieved encouraging results and changed the treatment methods of various cancers. CAR-T cell therapy targets cancer cells through genetically modified patients’ T cells, thereby achieving a significant cure rate for previously incurable cancers.   Currently, six CAR-T cell therapies have been approved by the US Food and Drug Administration (FDA), and several…

Read More >>